Journey Medical's Emrosi Demonstrates Superior Efficacy Over Oracea in Phase 3 Rosacea Trials
Key Insights
Journey Medical's Emrosi (search) (DFD-29) achieved 62.7% IGA treatment success compared to 39.0% for Oracea and 28.2% for placebo in combined Phase 3 trials (p<0.001).
The modified-release minocycline formulation reduced inflammatory lesions by 19.2 on average versus 14.8 for Oracea and 11.3 for placebo over 16 weeks.
The drug demonstrated a favorable safety profile with no major safety issues or serious adverse events related to the study drug in 653 patients.
Journey Medical Corporation has reported compelling efficacy data from its combined Phase 3 clinical trials evaluating Emrosi (search) (DFD-29), a modified-release minocycline formulation for rosacea (search) treatment. The pooled analysis of two multicenter, randomized, double-blind trials demonstrated statistically superior outcomes compared to both the current standard of care, Oracea, and placebo.
Phase 3 Trial Results Show Clear Superiority
The combined analysis of the MVOR-1 and MVOR-2 trials enrolled 653 subjects randomized in a 3:3:2 ratio to receive once-daily treatment with DFD-29, Oracea (40 mg doxycycline), or placebo for 16 weeks. Emrosi (search) achieved a 62.7% Investigator's Global Assessment (IGA) treatment success rate, significantly outperforming Oracea at 39.0% and placebo at 28.2% (p<0.001 for all comparisons).
The drug's efficacy extended to inflammatory lesion reduction, with DFD-29 patients experiencing a mean reduction of 19.2 inflammatory lesions from baseline to week 16. This compared favorably to reductions of 14.8 lesions with Oracea and 11.3 lesions with placebo, with statistical significance maintained across all comparisons (p<0.001).
Safety Profile Supports Clinical Use
Both Phase 3 trials demonstrated that DFD-29 was well tolerated, with no major safety issues or serious adverse events related to the study drug reported. The incidence and severity of treatment-emergent adverse events were comparable across all treatment groups, supporting the drug's safety profile for clinical use.
The most common adverse reaction reported by ≥1% of subjects treated with Emrosi (search) and more frequently than placebo was dyspepsia. The drug carries standard tetracycline-class warnings, including contraindications for patients with tetracycline hypersensitivity and precautions regarding use during pregnancy and childhood.
Addressing Significant Unmet Medical Need
Rosacea (search) affects over 16 million Americans and as many as 415 million people worldwide, according to The National Rosacea Society. The chronic, relapsing inflammatory skin condition most commonly presents with deep facial redness, acne-like inflammatory lesions, and spider veins, typically affecting adults between 30 and 50 years of age.
The condition's impact extends beyond physical symptoms, with surveys showing that more than 90% of rosacea (search) patients report lowered self-confidence and self-esteem. Among patients with severe symptoms, 88% said the disorder adversely affected their professional interactions, and 51% reported missing work due to their condition.
Clinical Conference Presentation Highlights Market Position
The efficacy data was presented at the 2025 Fall Clinical Dermatology Conference in Las Vegas, reinforcing the drug's clinical profile. Claude Maraoui, Co-Founder, President, and CEO of Journey Medical Corporation, stated that the results "reaffirm the strong efficacy and safety profile that have established Emrosi (search) as an important treatment option for patients with rosacea (search)."
Maraoui emphasized the company's belief that "Emrosi (search) has the potential to become the standard of care for rosacea (search)," highlighting the drug's position in the expanding dermatology market.
Modified-Release Formulation Offers Therapeutic Advantage
Emrosi (search) consists of 40 mg minocycline hydrochloride in a modified-release formulation, with 10 mg immediate release and 30 mg extended release components. This formulation design may contribute to its superior efficacy profile compared to the immediate-release doxycycline formulation used in Oracea.
The FDA-approved drug is currently available by prescription at specialty pharmacy chains for the treatment of inflammatory lesions of rosacea (search) in adults. Journey Medical, a commercial-stage pharmaceutical company focused on dermatological conditions, currently markets eight branded FDA-approved prescription drugs through its specialized sales and marketing model.